Search

everythinglearnresearchcommunity

for

Search:↓

Many young women with breast cancer experience poor quality of life, especially in sexual health and hair loss, but future outlook improves over time.

Insurance coverage for scalp cooling will make it more accessible to all chemotherapy patients.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Early detection and a multidisciplinary approach are crucial for improving gastric cancer survival rates.

A rare type of skin cancer on the scalp can be mistaken for hair loss, causing delayed diagnosis and severe damage.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

New therapies and trials are needed for Merkel cell carcinoma, a tough skin cancer.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Scalp cooling effectively reduces hair loss in breast cancer patients undergoing chemotherapy.

Lower levels of MYLK and CALD1 in bladder cancer and osteosarcoma are linked to worse survival rates.

New drug delivery systems show promise in effectively treating pathological scars.

Scalp cooling can effectively prevent hair loss during chemotherapy in pregnancy.

Managing inflammation and using vitamins can improve PRP therapy for better hair growth.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.

New regenerative medicine-based therapies for hair loss look promising but need more clinical validation.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.

Tumor proteins can both promote and suppress cancer, depending on the situation.

ATP-sensitive K+ channel subunits, particularly Sur2A, play a significant role in various cancers.

Tadalafil and Finasteride may help treat aggressive melanoma.

The document concludes that more research is needed to reduce frequent hospital visits, addiction medicine education improves with specific training, early breast cancer surgery findings are emerging, nipple smears are not very accurate, surgery for older melanoma patients doesn't extend life, a genetic condition in infants can often be treated with one drug, doctors are inconsistent with blood clot medication, a certain gene may protect against cell damage, muscle gene overexpression affects many other genes, and some mitochondrial genes are less active in mice with tumors.

Improving hair health and managing conditions can enhance scalp cooling effectiveness in preventing hair loss during chemotherapy.

More research and guidelines are needed for managing prostate cancer in people with high-risk genetic mutations.

Some drugs can cause permanent hair loss, though it's rare.

Metformin, a diabetes drug, may help prevent and treat various cancers, but more research is needed.

Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.